MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Inclusion Criteria:

- Has HIV-1 infection

- Is naïve to anti-retroviral therapy (ART).

- Is clinically stable, with no signs or symptoms of acute infection, at the time of
entry into the study

- Female is not pregnant, not breastfeeding, not a woman of childbearing potential
(WOCBP); but if WOCBP agrees to follow the contraceptive guidance

- All participants, male and female, agree to use barrier methods of contraception when
engaged in any sexual activity during treatment and for 6 weeks following treatment.

Exclusion Criteria:

- Is a user of recreational or illicit drugs or has had a history of drug or alcohol
abuse or dependence that may interfere with trial participation

- Has significant hypersensitivity or other contraindication to any of the components of
the study drugs

- Has a history of malignancy ≤5 years prior

- Female expects to donate eggs at any time during the study

- Is breastfeeding or expecting to conceive

- A WOCBP who has a positive urine pregnancy test on Day 1 before the first dose of
study treatment

- Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an
agent that is active against HIV-1

- Has used systemic immunosuppressive therapy or immune modulators within 30 days prior
to treatment in this study or is anticipated to need them during the course of the
study

- Requires any of the following prohibited medications: Carbamazepine, Phenobarbital,
Phenytoin, Rifabutin, Rifampin, Herbal remedies, St. John's Wort, Modafinil, Bosentan,
Nafcillin, Pentostatin

- Is currently participating in or has participated in an interventional clinical trial
with an investigational compound or device within 30 days of signing informed consent
to participate in this current trial

- Has a documented or known virologic resistance to any approved HIV-1 reverse
transcriptase inhibitor, protease inhibitor, integrase inhibitor

- Has active hepatitis C virus (HCV) coinfection defined as detectable HCV RNA or HBV
co-infection defined as hepatitis B surface antigen [HBsAg]-positive

- Has a current (active) diagnosis of acute hepatitis due to any cause

- Has previously been randomized in a study and received MK-8591, DOR, MK-1439A, or 3TC.